Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment

Atqiya Fariha; Ithmam Hami; Mahafujul Islam Quadery Tonmoy; Shahana Akter; Hasan Al Reza; Newaz Mohammed Bahadur; Md Mizanur Rahaman; Md Shahadat Hossain

doi:10.1016/j.heliyon.2022.e11081

Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment

Heliyon. 2022 Oct 13;8(10):e11081. doi: 10.1016/j.heliyon.2022.e11081. eCollection 2022 Oct.

Authors

Atqiya Fariha¹, Ithmam Hami¹, Mahafujul Islam Quadery Tonmoy¹, Shahana Akter¹, Hasan Al Reza², Newaz Mohammed Bahadur³, Md Mizanur Rahaman⁴, Md Shahadat Hossain¹

Affiliations

¹ Department of Biotechnology & Genetic Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
² Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh.
³ Department of Applied Chemistry and Chemical Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
⁴ Department of Microbiology, University of Dhaka, Dhaka, Bangladesh.

Abstract

Lung cancer is the primary cause of cancer related deaths worldwide. Limited therapeutic options and resistance to existing drugs are the major hindrances to the clinical success of this cancer. In the past decade, several studies showed the role of microRNA (miRNA) driven cell cycle regulation in lung cancer progression. Therefore, these small nucleotide molecules could be utilized as promising tools in lung cancer therapy. In this review, we highlighted the recent advancements in lung cancer therapy using cell cycle linked miRNAs. By highlighting the roles of the specific cell cycle core regulators affiliated miRNAs in lung cancer, we further outlined how these miRNAs can be explored in early diagnosis and treatment strategies to prevent lung cancer. With the provided information from our review, more medical efforts can ensure a potential breakthrough in miRNA-based lung cancer therapy.

Keywords: Biomarker; Cancer therapy; Cell cycle; NSCLC; miRNA.

Publication types

Review